Kyathanahalli Chandrashekara N, Tu Frank F, Ashenafi Gabriela, Schroer Margaret S, Hellman Kevin M
Department of Obstetrics and Gynecology, Endeavor Health, Evanston, IL, USA.
Department of Obstetrics and Gynecology, Pritzker School of Medicine, University of Chicago, Chicago, IL, USA.
Mol Pain. 2025 Jan-Dec;21:17448069251360092. doi: 10.1177/17448069251360092. Epub 2025 Jul 5.
Dysmenorrhea (period pain) affects over 40% of women and is a leading cause of missed school and workdays. However, the molecular mechanisms underlying this pain are not fully understood. We conducted a systematic review (Prospero registration: CRD42024535081) to identify and evaluate the biomolecules in menstrual effluent that may contribute to dysmenorrhea and assess how non-hormonal medications (e.g. NSAIDs) impact these biomarkers. Fifteen studies involving two hundred twenty-three participants met the inclusion criteria. We used the Newcastle-Ottawa Scale (for observational studies) and the Cochrane RoB2 tool (for randomized controlled trials) to evaluate the risk of bias and the quality of studies. Eight studies consistently reported elevated prostaglandin levels in the menstrual effluent of women with dysmenorrhea, though sample sizes were generally small, and methodological issues were noted. Seven studies demonstrated that NSAIDs reduce prostaglandin concentrations; however, these trials utilized multiple-day dosing protocols instead of single-dose regimens, leaving questions about acute treatment effects. Two studies highlighted alternative molecular targets, such as 12-HETE and platelet-activating factor (PAF), that may also play key roles in menstrual pain. Overall, elevated prostaglandins are a recurring finding, but the limited scope and design of existing studies indicate a need for larger, methodologically rigorous investigations. Nevertheless, the few studies that identified molecules other than prostaglandins suggest there are viable druggable targets for clinical trials to reduce menstrual pain.
痛经影响着超过40%的女性,是导致缺课和旷工的主要原因。然而,这种疼痛背后的分子机制尚未完全明确。我们进行了一项系统综述(国际前瞻性系统评价注册库登记号:CRD42024535081),以识别和评估月经流出物中可能导致痛经的生物分子,并评估非激素类药物(如非甾体抗炎药)如何影响这些生物标志物。15项涉及223名参与者的研究符合纳入标准。我们使用纽卡斯尔-渥太华量表(用于观察性研究)和Cochrane偏倚风险2工具(用于随机对照试验)来评估偏倚风险和研究质量。8项研究一致报告痛经女性月经流出物中的前列腺素水平升高,不过样本量一般较小,且存在方法学问题。7项研究表明非甾体抗炎药可降低前列腺素浓度;然而,这些试验采用的是多日给药方案而非单剂量方案,这使得急性治疗效果存在疑问。两项研究强调了其他分子靶点,如12-羟二十碳四烯酸(12-HETE)和血小板活化因子(PAF),它们可能在月经疼痛中也起关键作用。总体而言,前列腺素水平升高是一个反复出现的发现,但现有研究的范围和设计有限,表明需要进行更大规模、方法学严谨的调查。尽管如此,少数识别出前列腺素以外分子的研究表明,存在可行的可成药靶点用于临床试验以减轻月经疼痛。